Defendant
2 cases as defendant.
Tecan Genomics Inc. is a U.S.-based subsidiary of Tecan Group Ltd., a publicly traded Swiss company (SIX: TECN) founded in 1980. Tecan Group Ltd. has its global headquarters in Männedorf, Switzerland, with Tecan Genomics Inc. located in Morgan Hill, California. As of 2023, the parent company employed over 3,500 people and reported sales of CHF 946 million in 2021, with a market capitalization of CHF 4,390 million as of December 31, 2023.
Tecan Group Ltd. is a leading global provider of laboratory instruments and solutions for the biopharmaceutical, forensic, clinical diagnostics, and medical technology sectors, specializing in laboratory automation. Tecan Genomics Inc., which was formerly NuGEN Technologies (acquired by Tecan in 2018), specifically focuses on genomics applications. It develops and sells innovative genomic sample preparation solutions, including automated workstations and reagents for next-generation sequencing (NGS) and microarrays. Key product lines include solutions for DNA/RNA extraction, quantification, PCR set-up, and NGS library preparation, such as the DreamPrep and MagicPrep NGS systems.
In terms of patent litigation, Tecan Genomics Inc. appears to be an operating company actively asserting its intellectual property. The company has a record of one tracked case as a plaintiff and zero as a defendant, indicating a posture of enforcing its patents rather than primarily defending against assertions. The single tracked case, Tecan Genomics Inc v. QIAGEN Sciences LLC, was filed on October 6, 2023, in the Delaware District Court.
An inter partes review (IPR) was initiated by Unified Patents against Tecan Genomics Inc. concerning US patent 10036012. This case has reached a final written decision.
An inter partes review (IPR) proceeding at the Patent Trial and Appeal Board concerning US patent 11098357, where Unified Patents PTAB Data is the petitioner and Tecan Genomics Inc. is the patent owner. The case is currently filed with a final written decision.